Radioligand Therapy For Cancer Research Landscape

Generated: August 7, 2026

Report Type: Research Intelligence

Data Sources: NIH RePORTER, ClinicalTrials.gov, USPTO, PubMed

How to Use This Report

NIH funding patterns validate research direction. Knowing who is funded in your space - with what methods, in what collaborations, and at what scale - calibrates where your work fits relative to the field's momentum and reveals gaps worth pursuing.

The intelligence in this report comes primarily from our semantic analysis across the linked data, not from any single source. NIH RePORTER, ClinicalTrials.gov, USPTO, and PubMed are all publicly searchable - anyone can look up individual records. Our value is in:

• Identifying conceptually-related projects via AI semantic search rather than brittle keyword matching
• Cross-linking each project to its associated patents, clinical trials, and publications
• Synthesizing across the analyzed sample to surface patterns no single record reveals - methodological trends, collaboration networks, gap analysis, and positioning signals

The Market Context section adds external color sourced via live web search. It is supplementary to the core analysis above.

What This Report Does Not Cover

A short, upfront note on the boundaries of this analysis. We surface this so you can read everything below with the right calibration.

• Companies are in this data - non-NIH-funded internal R&D is not. SBIR/STTR grantees, academic-industry partnerships, and commercial entities receiving NIH funding do appear and carry real commercial weight. What's invisible is privately-funded R&D inside companies that doesn't intersect with an NIH grant.
• International activity is largely outside the sample. NIH RePORTER captures US grantees and their direct collaborators. Major work in Europe, China, Japan, and elsewhere is not reflected unless tied to a US-funded project.
• Linked outputs require an NIH grant acknowledgment. A clinical trial, patent, or publication only appears here if it was filed with an NIH project number. Industry-led trials, non-USPTO patents, and papers without NIH funding acks are missing - even when central to the field.
• Recent quarter activity may be incomplete. NIH RePORTER updates with a lag of several weeks; some current-fiscal-year awards may not yet be visible.
• Umbrella institutional grants are not credited to topic funding. Some trials and patents in this report are hosted under broad institutional support awards (P30 cancer centers, CTSA hubs, training grants) whose parent grant covers many programs beyond this topic. Those records appear in the trials and patents sections, but the host grants' dollars are deliberately excluded from Total Committed Funding to keep the headline number topically attributable. Real topic activity at those institutions is therefore likely higher than the funding figures alone suggest.
• Market context is web-sourced, not exhaustive - see the Sources subsection in Market Context for what was retrieved.
• Project categorization is automated. A single primary category is assigned per project by AI classification, with confidence scores. Some boundary cases (especially infrastructure vs. biotools) may be misassigned.

This is depth-over-breadth analysis - high signal on what NIH funds and produces, including its commercial recipients. For a complete literature view, supplement with broader PubMed/Web of Science searches and conference proceedings.

Executive Summary

Of 121 projects totaling $113.8M across 52 organizations, the therapeutics funding category dominates at 75.2% of projects (91 of 121, $87.0M), with biotools at 9.9% (12 of 121, $8.7M) and basic research at 5.8% (7 of 121, $8.9M). Annual NIH commitments rose from $43.2M in FY2024 to $57.1M in FY2025, though two data points do not establish a trend. Among 70 tracked trials, 62 are in progress, planned, or completed versus 8 terminated, suspended, or withdrawn; the terminated and withdrawn subset warrants monitoring but no specific cause can be attributed from this dataset. University of California San Francisco, Johns Hopkins, Washington University, University of Wisconsin-Madison, and Sloan-Kettering together account for a disproportionate share of project count and top-funded awards, with Johns Hopkins' P01 alone at $5.7M.

The sharpest cleavage in the sample is between beta-emitter programs - where Lu-177/PSMA and Lu-177/DOTATATE are heavily represented and clinically validated - and alpha-emitter programs (Ac-225, Pb-212, At-211, Ra-223), which appear across roughly a dozen projects but remain predominantly preclinical or early-phase. A second cleavage separates direct-kill radiopharmaceutical approaches from combination strategies: radioimmunotherapy plus checkpoint inhibitors, RLT plus CAR-T, and RLT plus PARP inhibition each appear as distinct funded clusters, reflecting a broad bet that monotherapy efficacy ceilings will require combination solutions. Within the funding category taxonomy, dosimetry and treatment personalization - including SPECT-guided dosimetry and deep learning-based treatment planning - constitute a thin but growing subset cutting across therapeutics and biotools, suggesting this is an area where methodological investment lags clinical deployment.

For a researcher mapping entry points, the sample shows sparse coverage of resistance mechanisms to established RLT (only a handful of projects address PSMA-therapy resistance or tumor microenvironment-mediated escape), and the combination of alpha-emitter chelator chemistry with theranostic imaging pairs (Pb-203/212, Ac-225/lanthanide surrogates) represents a methodologically active zone where new chelation chemistry and isotope production capacity are co-limiting factors worth tracking. Collaboration opportunities exist between dosimetry-focused groups (several at Michigan and Johns Hopkins) and emerging alpha-particle programs that currently lack dosimetry infrastructure. Grant mechanisms worth noting: several K08/K99 awards in this sample are positioned at the radioimmunology interface, suggesting NIH is seeding early-career researchers in combination-therapy design - a signal that this mechanistic territory is considered fundable at the investigator-initiation level.

What Surprised Us

Non-obvious findings detected algorithmically from the data, then interpreted. These are flagged hypotheses, not verified conclusions - patterns worth investigating rather than facts to act on directly. Broader NIH ratios are directional at low topic-sample counts and could reflect real gaps OR taxonomy artifacts; treat individual findings as starting points for deeper diligence.

1. 6 of the top-funded PIs hold their entire NIH-linked funding on a single project with no adjacent follow-on

When high-dollar investigators have no visible NIH-linked follow-on activity, it raises a question about continuity risk: if a single grant concludes or is not renewed, that research thread may stall with no funded successor project in the pipeline visible in this sample. Across 6 PIs representing $18.5M in combined single-project awards, the pattern is concentrated enough to warrant attention from funders or collaborators tracking workforce and portfolio resilience in this space. This does not mean follow-on work is absent entirely - investigators may be transitioning to industry partnerships, non-NIH funding, or commercial vehicles that are not captured in this sample to this dataset. Confidence: Low - Evidence: 6 PIs, $18.5M combined, single-project awards with no adjacent NIH-linked follow-on visible in the sample.

2. A subset of highly-funded organizations publishes actively but shows no linked patents or trials in the NIH-linked sample

Two organizations with 10 combined projects, $9.3M in NIH funding, and 32 linked publications show zero linked patents and zero linked trials within this dataset, suggesting a gap between discovery output and downstream translational milestones as visible through NIH acknowledgment. For researchers or investors scoping the field, this pattern may flag organizations that are productive at the science layer but have not yet - or have not yet visibly - converted that output into IP filings or clinical-stage work within the NIH-linked record. However, the NIH-linked sample only captures work acknowledging NIH project numbers: commercial patent filings, international IP, and industry-sponsored trials would all fall outside this analysis, so the absence here should be treated as a signal worth investigating rather than a definitive characterization of these organizations' commercial posture. Confidence: Low - Evidence: 2 organizations, 10 projects, $9.3M combined funding, 32 linked publications, 0 linked trials and 0 linked patents in the analyzed sample.

Field Maturity Assessment

Note: This assessment is based on NIH-linked clinical trials, patents, and publications. It reflects patterns in the analyzed sample and may not represent the full global research landscape.

Technology Readiness: TRL 7-8

Overall Assessment: Established - Commercial applications exist

Historical Reference Point: TRL 7-8 is comparable to where checkpoint inhibitor immunotherapy (anti-PD-1/PD-L1 agents) sat roughly in 2014-2016, after pembrolizumab and nivolumab received initial FDA approvals but while the field was still running numerous Phase 1 and Phase 2 trials to expand indications and combination regimens.

Based on the linked trials and publications, radioligand therapy for cancer appears to be at TRL 7-8, reflecting a technology that has moved well beyond proof-of-concept and is operating in late-stage clinical and commercial contexts. The trial distribution across 70 linked trials - spanning Phase 1 (31), Phase 2 (23), and Phase 3 (2), with 59 interventional trials of which 56 carry a phase label (a subset of the 59 interventional trials in the sample) - indicates a maturing pipeline where early-stage exploration coexists with late-stage validation, consistent with a field that already has approved products (e.g., lutetium-177 DOTATATE and lutetium-177 PSMA-617) and is now expanding indications and combinations. The 744 linked publications with a low 5% preprint ratio further supports an established evidence base rather than a speculative frontier, and NIH funding of $113.8M across 121 linked projects in the sample - with therapeutics as the top category - reinforces that the primary investment axis is translational and clinical rather than purely basic.

Confidence: High - Evidence: 70 total trials with Phase 3 presence, 744 linked publications with 5% preprint ratio, $113.8M NIH funding across 121 projects, and approved products in the field corroborate a consistent late-TRL signal across three independent streams.

Supporting Evidence

• Publication Maturity: With 744 linked publications, the 5% preprint ratio (approximately 34 preprints) is interpretable at this sample size and suggests a predominantly peer-reviewed, established literature base rather than a rapidly emerging one where preprints would likely dominate - this pattern is consistent with a field that has accumulated substantial peer-reviewed clinical and mechanistic evidence over multiple decades.

Confidence: High - Evidence: 744 total linked publications, 34 preprints (~5% of sample).

• Clinical Progression: The trial phase distribution across 70 linked trials - 31 Phase 1, 23 Phase 2, and 2 Phase 3, with 8 observational trials and 14 trials carrying N/A or Unknown phase labels - reflects a pipeline that is both active at early stages (likely new targets and combinations) and has demonstrated late-stage viability, a pattern typical of a field with at least one approved modality expanding into adjacent indications rather than a wholly pre-approval field.

Confidence: High - Evidence: 70 total linked trials; phase distribution: 31 Phase 1, 23 Phase 2, 2 Phase 3, 11 N/A, 3 Unknown; 59 interventional, 8 observational.

• IP Activity: With only 5 linked patents and 0 filed in the last two years (0% recency ratio), the patent sample is too small to interpret recency ratios as a meaningful trend signal; this low count most likely reflects the scope of NIH-linked patent data rather than a field-level absence of IP activity, given that radioligand therapy involves substantial proprietary chemistry and radiolabeling technology held by commercial entities outside NIH's direct patent portfolio.

Confidence: Low - Evidence: only 5 linked patents in the sample, 0 recent; sample size precludes trend inference.

Strategic Implications

For a researcher entering this space, the field's maturity means that broad, first-in-class mechanistic proposals are likely to face higher bars for novelty - the most fundable angle in the NIH-linked sample sits in therapeutics (the top funding category among 121 linked projects), suggesting that proposals framing radioligand optimization, novel target-ligand combinations, or combination-regimen rationale within translational or clinical contexts are better positioned than purely basic mechanistic work. The FY2024 to FY2025 NIH funding in the linked sample rose from $43.2M to $57.1M, though two data points do not establish a trend, and FY2026 YTD of $13.5M should not be interpreted as a decline given the partial-year reporting period ending September 30, 2026. Given the Phase 1-heavy trial distribution (31 of 70 linked trials), researchers with access to radiopharmacy infrastructure or oncology clinical partners are likely to find collaborative R01 or U01 mechanisms productive for addressing dosimetry, combination safety, or biomarker-stratification questions that the current trial volume has surfaced but not fully resolved.

Confidence: Medium - Evidence: 121 NIH-linked projects, therapeutics as top category, FY2024-FY2025 funding figures ($43.2M and $57.1M), 31 Phase 1 trials of 70 total linked trials; strategic inference rests on NIH-linked scope and two funding years, limiting generalizability.

Competitive Topology

Note: Key players listed below are derived from NIH-funded project data and represent academic/research institutions. Commercial entities may not appear. The 5 clusters below are the methodological groupings the synthesis identified as most distinct in the analyzed abstracts - clusters are cross-cutting (a single project can belong to more than one), and a different cut of the data could resolve at 3 or 6 clusters rather than 5.

Among the funded projects, the competitive topology is organized around five technically distinct approaches that range from the fully commercial (177Lu small-molecule/peptide PRRT with FDA-approved agents) to the early-stage (alpha-RPT theranostic pairs and immunoradiation combinations). The most densely funded area by project count is immunoradiation - combining RPT with immune checkpoint inhibitors, CAR-T, or vaccines - with approximately 18 projects, closely followed by small-molecule/peptide beta-emitter RLT (approximately 16 projects) which benefits from approved anchors but faces resistance and personalization challenges that drive continued NIH investment.

Confidence: High - Evidence: 121 total projects analyzed, with cross-source corroboration from patents, clinical trials, and P01/P50 program-level awards across all five clusters.

Dosimetry and quantitative imaging infrastructure (approximately 8 projects, 3 commercial entities) represents a horizontal enabler that cuts across all four therapeutic clusters rather than competing with them, and its commercial maturation via SBIR/R44 mechanisms signals that tool-layer investment is accelerating in parallel with therapeutic development.

Confidence: High - Evidence: 3 commercial organizations (RADIOPHARMACEUTICAL IMAGING AND DOSIMETRY LLC, AIQ GLOBAL INC, QSCINT IMAGING SOLUTIONS LLC) appear in the NIH sample alongside academic dosimetry R01s at Michigan, Johns Hopkins, and Yale, with 3 dedicated clinical dosimetry trials.

Methodological Clusters

Confidence: High - Evidence: approximately 15 projects across 10+ organizations including dedicated P01 program at Johns Hopkins, 2 companion patents (University of Iowa), and 2 early-phase clinical trials in the dataset.

Confidence: High - Evidence: approximately 14 projects across 10 organizations, 2 Phase 2 trials (lymphoma) and 1 Phase 1 trial in the clinical dataset, plus astatine-211 anti-CD45 construct in active Fred Hutchinson trials.

Confidence: High - Evidence: approximately 16 projects across 10+ organizations, multiple ongoing Phase N/A dosimetry and pharmacokinetics trials at Michigan and Johns Hopkins, 1 Phase 1/2 pediatric 177Lu-DOTATATE trial (Nationwide Children's), and direct PSMA resistance trial at UCSF.

Confidence: High - Evidence: approximately 8 projects across 9 organizations including 3 commercial entities, 3 clinical trials focused specifically on dosimetry workflows (SPECT/CT pharmacokinetics trials at Johns Hopkins and Michigan, AIQ theranostics response assessment trial), and 1 dedicated SPECT collimator technology R01.

Confidence: High - Evidence: approximately 18 projects across 10+ organizations, 3 patents (University of Wisconsin-Madison) explicitly linking targeted radiotherapy chelates to immune modulation, 1 active clinical trial on RPT resistance/immune mechanisms at UCSF, and multiple P01/P50 program project awards anchoring this approach.

Strategic Implications

For a researcher entering this space, the most competitive area to enter is beta-emitter PRRT/RLT for PSMA-positive prostate cancer and neuroendocrine tumors, where the field is crowded with funded projects and approved products already define the standard of care, making incremental positioning difficult without a differentiated mechanistic angle. Differentiation opportunities favor alpha-RPT theranostic development for non-PSMA targets (for example NTSR1, CXCR4, melanocortin-1 receptor, DLL3) or radioimmunotherapy constructs for hematologic malignancies, both of which show active but less saturated NIH funding and carry stronger IP whitespace relative to the beta-emitter cluster. For new lab positioning, dosimetry and AI-driven treatment planning represent a tractable entry via R01 or R21 mechanisms with a clear translational deliverable, since the infrastructure cluster is underrepresented in academic lab count relative to its commercial interest and clinical need. Labs seeking to build a distinctive program in immunoradiation combinations should consider P01 or U01 mechanisms given the multi-investigator, multi-target structure that already defines the funded leaders in that space, and should prioritize mechanistic work on resistance and immune contexture since that angle is active in Phase N/A trials but lightly covered by the existing grant portfolio.

Confidence: High - Evidence: 121 projects analyzed across 5 clusters, with cluster sizes ranging from approximately 8 (dosimetry) to approximately 18 (immunoradiation), cross-validated against 5 patents, 10 clinical trials, and SBIR/R44 commercial-stage awards.

White Space Analysis

This section maps what NIH-funded research covers vs. what's underrepresented within the topic scope. Private R&D, international research, and non-NIH federal funding (DoD, DARPA, industry) are not captured here. Broader-NIH counts are filtered to radioligand therapy research scope so comparisons are topically apples-to-apples. Sample counts match against title AND abstract for the analyzed project set; broader-NIH counts match against title ONLY (abstracts aren't full-text-indexed at query time), so broader counts are directional lower bounds.

Base rate for "Broader NIH" columns: every broader-NIH cell below is drawn from 149 NIH projects matching the radioligand therapy research scope filter - not the full ~154K RePORTER universe. Read broader-NIH counts as shares of that 149-project scope, not of all NIH funding.

How to read this section. Each of the 5 dimensions below is a different axis (e.g., Production Platform, Therapeutic Target). For each project we check whether its title or abstract mentions any keyword in any of that dimension's categories. If yes, the project is matched on that axis. If no, it's unclassified on that axis - usually because the project doesn't foreground that particular axis (a "cell-free antibody discovery for HIV" project foregrounds Engineering and Therapeutic Target but rarely names a specific Antibody Format, so it lands unclassified on Format). A project can be matched on some axes and unclassified on others. High unclassified rates on an axis typically mean the sample doesn't foreground that axis - not that the projects are broken or the taxonomy is wrong.

Overview

Across 121 NIH-funded projects totaling $113.8M, radioligand therapy research shows strong concentration in theranostic infrastructure and dosimetry-safety work, with prostate cancer and antibody-based targeting vectors dominating their respective dimensions, while several cancer types, radionuclide classes, and targeting scaffold categories remain sparsely covered within this sample. The Dosimetry, Imaging, and Theranostic Infrastructure dimension matched 72 of 121 projects, and the Combination Strategy dimension matched 69 of 121, indicating these are the most actively framed research angles; by contrast, the Radionuclide and Particle Type dimension matched only 33 of 121 projects (27.3%), suggesting most projects do not foreground isotope identity in their titles or abstracts as captured here. Coverage data derive from NIH RePORTER, which represents publicly searchable federal NIH funding - the largest single source of non-dilutive US biomedical grants - but excludes private industry R&D, international programs, and non-NIH federal funding (e.g., DoD, DOE), so activity in those sectors is not reflected here. Broader NIH counts in this report are based on project title matching only, making them a conservative floor rather than a comprehensive census of NIH-wide activity.

Confidence: High - Evidence: 121 projects analyzed across 5 dimensions, 93.4% on-topic sample, broader NIH counts are title-only floor estimates.

Coverage by Cancer Type Targeted

Primary cancer indication or tumor type being targeted by the radioligand or radionuclide therapy approach

[†] Rows marked with a dagger are broader-NIH outliers - either their broader count is much higher than the dimension median (>=5x) or the category name contains a generic biomedical term ("machine learning", "biomarker", "methylation") that over-matches within the topic scope. These counts likely reflect generic keyword prevalence within the scope-filtered universe rather than topic-specific activity. Treat as directional only; do not anchor coverage inferences on daggered cells.

Rows are non-exclusive: a project can appear in more than one category, so the sum of the Projects column can exceed 62 classified projects.

Keywords per category (what was counted):

• Prostate Cancer: prostate cancer, prostate tumor, psma, prostate carcinoma, castration-resistant prostate, metastatic prostate, crpc, prostate adenocarcinoma
• Neuroendocrine Tumors: neuroendocrine tumor, neuroendocrine neoplasm, net, carcinoid, pheochromocytoma, paraganglioma, somatostatin receptor, prrt, peptide receptor radionuclide
• Liver and Hepatocellular Carcinoma: liver cancer, hepatocellular, hcc, hepatoma, liver tumor, hepatic malignancy, liver carcinoma
• Glioma and Brain Tumors: glioblastoma, glioma, gbm, brain tumor, brain cancer, il13ra2, astrocytoma, brain metastasis, intracranial tumor
• Neuroblastoma: neuroblastoma, pediatric neuroblastoma, mibg, meta-iodobenzylguanidine, neuroblastoma therapy
• Colorectal Cancer: colorectal cancer, colon cancer, rectal cancer, colorectal carcinoma, crc, ntsr1, neurotensin receptor, colorectal tumor
• Lung Cancer: lung cancer, nsclc, sclc, lung tumor, lung adenocarcinoma, non-small cell lung, small cell lung, lung carcinoma
• Breast Cancer: breast cancer, breast tumor, breast carcinoma, her2, triple negative breast, tnbc, breast adenocarcinoma
• Melanoma: melanoma, malignant melanoma, cutaneous melanoma, uveal melanoma, metastatic melanoma, melanocyte
• Leukemia and Myeloid Malignancies: leukemia, aml, acute myeloid leukemia, cml, myelodysplastic, mds, bone marrow malignancy, myeloid neoplasm, integrin beta-2
• Lymphoma: lymphoma, hodgkin lymphoma, non-hodgkin lymphoma, nhl, diffuse large b-cell, dlbcl, follicular lymphoma, cd20
• Head and Neck Cancer: head and neck cancer, head and neck squamous, hnscc, oral cancer, pharyngeal cancer, laryngeal cancer, head and neck tumor

In the Cancer Type Targeted dimension, prostate cancer is the dominant indication with 20 projects (16.5% of the sample) and $15.6M, reflecting the clinical prominence of PSMA-targeted radioligand therapy; lung cancer is the second most represented at 11 projects (9.1%, $11.3M), followed by neuroendocrine tumors and colorectal cancer each at 7 projects (5.8%). Notably, 59 of 121 projects (48.8%) are unclassified in this dimension, meaning nearly half the sample does not foreground a specific cancer type - consistent with platform-level or mechanism-focused research. Glioma and brain tumors, melanoma, and lymphoma each appear in only 1 project (0.8%) within this dimension; the broader NIH counts for these (3, 3, and 0 respectively) are too sparse to draw coverage conclusions beyond noting they are minimally represented in the analyzed sample.

Confidence: High - Evidence: 62 of 121 projects classified, top category prostate at 16.5%, 59 unclassified projects.

Coverage by Radionuclide and Particle Type

Type of radioactive isotope or particle emission used in the therapy agent

[†] Rows marked with a dagger are broader-NIH outliers - either their broader count is much higher than the dimension median (>=5x) or the category name contains a generic biomedical term ("machine learning", "biomarker", "methylation") that over-matches within the topic scope. These counts likely reflect generic keyword prevalence within the scope-filtered universe rather than topic-specific activity. Treat as directional only; do not anchor coverage inferences on daggered cells.

Rows are non-exclusive: a project can appear in more than one category, so the sum of the Projects column can exceed 33 classified projects.

Keywords per category (what was counted):

• Alpha Particle Emitters: alpha particle, alpha emitter, alpha-particle emitter, alpha radiation, actinium-225, ac-225, bismuth-213, bi-213, astatine-211, at-211, thorium-227, th-227, radium-223, ra-223, lead-212, pb-212
• Beta Particle Emitters: beta emitter, beta particle, beta radiation, lutetium-177, lu-177, yttrium-90, y-90, iodine-131, i-131, copper-67, cu-67, rhenium-188, re-188, phosphorus-32
• Auger Electron Emitters: auger electron, auger emitter, auger radiation, iodine-125, i-125, indium-111, in-111, gallium-67, ga-67, tin-117m, sn-117m
• Radium-223 Specifically: radium-223, ra-223, radium dichloride, xofigo, radium therapy, radium combination
• Lutetium-177 Specifically: lutetium-177, lu-177, 177lu, lutetium psma, lutetium dotatate, lutetium therapy, lutetium theranostic
• Actinium-225 Specifically: actinium-225, ac-225, 225ac, actinium psma, actinium therapy, actinium labeled
• Positron and Dual-Use Isotopes: copper-64, cu-64, iodine-124, i-124, zirconium-89, zr-89, gallium-68, ga-68, fluorine-18, f-18, theranostic pair, matched pair isotope
• Novel and Emerging Radionuclides: terbium-149, tb-149, fermium-255, astatine-211, bismuth-212, bi-212, samarium-153, holmium-166, emerging radionuclide, novel isotope
• Copper Isotopes Specifically: copper-67, copper-64, 67cu, 64cu, cu-67, cu-64, copper radionuclide, copper theranostic
• Lead Isotopes Specifically: lead-212, lead-203, pb-212, pb-203, 212pb, 203pb, lead-212 therapy, lead theranostic
• Radioiodine and Iodine Isotopes: radioiodine, iodine-131, iodine-124, i-131, i-124, 131i, radioiodine therapy, thyroid radioiodine
• High-LET Particle Therapy Combinations: high-let, high linear energy transfer, combined let, let molecular radiotherapy, high-let radiotherapy, mixed particle radiation

The Radionuclide and Particle Type dimension has the lowest match rate of any dimension, with only 33 of 121 projects (27.3%) classified, reflecting that most funded projects describe therapeutic or biological outcomes without foregrounding specific isotope chemistry in accessible title or abstract text. Alpha particle emitters are the leading category with 14 projects (11.6%, $15.0M), and lutetium-177 and lead isotopes are each specifically named in 7 projects (5.8%), while beta particle emitters appear as a general class in only 3 projects (2.5%) despite lutetium-177 - the most clinically deployed beta emitter - having its own category. Auger electron emitters (1 project, 0.8%), actinium-225 (1 project, 0.8%), and radium-223 (1 project, 0.8%) are each represented by a single project in this dimension; the broader NIH counts for these categories (0, 0, and 1 respectively) are all below 30 and do not support coverage conclusions beyond noting minimal representation.

Confidence: Medium - Evidence: 33 of 121 projects classified (27.3%), high unclassified rate may reflect abstract-level vocabulary rather than true absence of isotope-specific work.

Coverage by Targeting Vector and Molecular Scaffold

The molecular carrier or ligand used to deliver the radionuclide to the tumor target

[†] Rows marked with a dagger are broader-NIH outliers - either their broader count is much higher than the dimension median (>=5x) or the category name contains a generic biomedical term ("machine learning", "biomarker", "methylation") that over-matches within the topic scope. These counts likely reflect generic keyword prevalence within the scope-filtered universe rather than topic-specific activity. Treat as directional only; do not anchor coverage inferences on daggered cells.

Rows are non-exclusive: a project can appear in more than one category, so the sum of the Projects column can exceed 38 classified projects.

Keywords per category (what was counted):

• Small Molecule Ligands and Inhibitors: small molecule, psma ligand, psma inhibitor, dota-psma, urea-based ligand, peptidomimetic, small molecule radioligand, low molecular weight
• Peptide-Based Carriers: peptide receptor, radiolabeled peptide, dotatate, dotatoc, octreotide, somatostatin analog, bombesin, rgd peptide, peptide conjugate, cyclic peptide
• Antibody and Antibody Fragment Conjugates: antibody conjugate, radioimmunotherapy, radiolabeled antibody, antibody chelator conjugate, monoclonal antibody, antibody fragment, fab fragment, scfv, igg conjugate, radioimmunoconjugate
• Nanobodies and Single-Domain Antibodies: nanobody, single-domain antibody, vhh, camelid antibody, sdab, radiolabeled nanobody, nano-antibody
• Affibodies and Non-Antibody Protein Scaffolds: affibody, darpin, adnectin, knottin, cystine knot, protein scaffold, engineered scaffold protein, non-antibody scaffold
• Nanoparticle and Liposomal Carriers: nanoparticle, liposome, lipid nanoparticle, polymeric nanoparticle, nanoconstruct, radiolabeled nanoparticle, nanocarrier, dendrimer
• Engineered Bacterial and Gene-Based Reporters: bacterial reporter, gene fusion, reporter gene, radiotheranostic reporter, nis gene, sodium iodide symporter, genetic reporter, viral vector delivery
• Pretargeting Strategies: pretargeting, pretargeted radioimmunotherapy, bioorthogonal, click chemistry, tetrazine ligation, bispecific pretargeting, two-step targeting, mskcc pretargeting
• TGF-Beta and Microenvironment-Targeted Ligands: tgfβ targeted, tgf-beta ligand, tumor microenvironment targeted, stromal targeting, fibroblast activation protein, fap, microenvironment ligand
• Chelator and Radiometal Coordination Scaffolds: chelator, radiochelation, theranostic isotope, rare earth isotope, lead-212, actinium chelation, bifunctional chelator, radiometal coordination
• Exosome and Extracellular Vesicle Carriers: exosome, extracellular vesicle, exosome-mediated, vesicle delivery, tumor-derived vesicle, exosomal carrier, ev-based therapy
• Extracellular Matrix and Tumor Microenvironment Scaffold Ligands: extracellular matrix, ecm-targeted, tumor microenvironment scaffold, matrix-targeted radiopharmaceutical, collagen-targeted, fibronectin-targeted, stromal targeting, microenvironment ligand

In the Targeting Vector and Molecular Scaffold dimension, antibody and antibody fragment conjugates dominate with 18 projects (14.9% of the sample, $18.0M), while nanoparticle and liposomal carriers represent a meaningful secondary cluster at 7 projects (5.8%, $6.2M); 83 of 121 projects (68.6%) are unclassified, again suggesting platform and mechanism framing dominates the sample. Nanobodies and single-domain antibodies, and affibodies and non-antibody protein scaffolds each appear in 0 projects (0.0%) in this dimension, with broader NIH counts of 0 for both - too sparse to interpret as a coverage signal, but notable as scaffold classes with active preclinical interest in the broader literature. The broader NIH count for antibody and antibody fragment conjugates stands at 20, which is broadly consistent with its sample representation (14.9%) and does not appear anomalous relative to peer categories in this dimension.

Confidence: Medium - Evidence: 38 of 121 projects classified, antibody conjugates at 14.9% concentration, 83 unclassified projects limit interpretation.

Coverage by Combination Strategy and Mechanistic Approach

The therapeutic combination or mechanistic strategy used alongside or within the radioligand therapy

[†] Rows marked with a dagger are broader-NIH outliers - either their broader count is much higher than the dimension median (>=5x) or the category name contains a generic biomedical term ("machine learning", "biomarker", "methylation") that over-matches within the topic scope. These counts likely reflect generic keyword prevalence within the scope-filtered universe rather than topic-specific activity. Treat as directional only; do not anchor coverage inferences on daggered cells.

Rows are non-exclusive: a project can appear in more than one category, so the sum of the Projects column can exceed 69 classified projects.

Keywords per category (what was counted):

• Radioligand Therapy with Immune Checkpoint Inhibitors: immune checkpoint, checkpoint inhibitor, pd-1, pd-l1, ctla-4, anti-pd-1, anti-pd-l1, checkpoint blockade, immunotherapy combination, checkpoint combination
• Radioligand Therapy with External Beam Radiotherapy: external beam radiotherapy, ebrt, combination radiotherapy, radiosensitizer, stereotactic body, sbrt, hypofractionated, conventional radiotherapy, radiotherapy combination, external beam radiation
• Radioligand Therapy with CAR T Cell Therapy: car t cell, chimeric antigen receptor, car-t, adoptive cell therapy, t cell therapy, car nk, cellular immunotherapy combination
• Radioligand Therapy with Cancer Vaccines: cancer vaccine, tumor vaccine, antitumor vaccine, vaccine combination, radiation and vaccine, abscopal vaccine, neoantigen vaccine
• Radioligand Therapy for Tumor Immunomodulation: immunomodulation, immune priming, abscopal effect, innate immunity, immune activation, tumor immunity, immune response, immunogenic cell death, cgas-sting, type i interferon
• Receptor Upregulation and Target Expression Modulation: receptor upregulation, target expression, psma expression, somatostatin receptor upregulation, target modulation, epigenetic upregulation, receptor regulation, melt, expression enhancement
• Combination Radioligand Therapy Regimens: combination radioligand therapy, dual radioligand, tandem radioligand, radioligand combination, multi-agent radioligand, sequential radioligand, combination radionuclide therapy
• Chemotherapy and Radiosensitization: chemotherapy combination, radiosensitizer, chemosensitization, cytotoxic combination, dna damage sensitizer, platinum combination, chemotherapy and radionuclide
• Targeted Therapy and Signal Inhibitor Combinations: parp inhibitor, kinase inhibitor, targeted therapy combination, small molecule inhibitor combination, dna repair inhibitor, atr inhibitor, hormone therapy combination, androgen deprivation
• Bone Marrow and Hematopoietic Conditioning: bone marrow conditioning, hematopoietic stem cell, myeloablative, bone marrow niche, myeloid conditioning, stem cell transplant conditioning, selective bone marrow
• Alpha Particle Emitter Radiopharmaceutical Therapy: alpha particle, alpha-emitter, targeted alpha therapy, tat, alpha radionuclide, actinium, bismuth, lead-212, astatine
• Theranostic Radiopharmaceutical Development and Dosimetry Optimization: theranostic, radiotheranostic, dosimetry, theranostics, paired imaging therapy, radiopharmaceutical dosimetry, theranostic agent, dosimetry-guided

Within the Combination Strategy and Mechanistic Approach dimension, theranostic radiopharmaceutical development and dosimetry optimization is by far the largest category at 34 projects (28.1% of the sample, $31.9M), with its broader NIH count of 56 being notably higher than all other categories in this dimension - the next highest broader NIH counts are 7 for immune checkpoint inhibitor combinations and alpha particle emitter therapy; the 56 broader NIH matches for theranostics may partly reflect broad keyword prevalence and should be treated as directional rather than precise. Alpha particle emitter radiopharmaceutical therapy represents 15 projects (12.4%, $11.8M) and immune checkpoint inhibitor combinations represent 11 projects (9.1%, $9.8M), forming the next tier of activity. Radioligand therapy with cancer vaccines and targeted therapy plus signal inhibitor combinations each appear in 0 projects (0.0%) with broader NIH counts of 0, too sparse to characterize as gaps; bone marrow and hematopoietic conditioning and chemotherapy/radiosensitization each appear in only 1 project (0.8%) in this dimension.

Confidence: Medium - Evidence: 69 of 121 projects classified, theranostics category at 28.1%, broader NIH count of 56 flagged as potentially inflated by keyword breadth.

Coverage by Dosimetry, Imaging, and Theranostic Infrastructure

Tools, platforms, and methodologies supporting dosimetry quantification, companion imaging, and personalization of radioligand or radionuclide therapy

[†] Rows marked with a dagger are broader-NIH outliers - either their broader count is much higher than the dimension median (>=5x) or the category name contains a generic biomedical term ("machine learning", "biomarker", "methylation") that over-matches within the topic scope. These counts likely reflect generic keyword prevalence within the scope-filtered universe rather than topic-specific activity. Treat as directional only; do not anchor coverage inferences on daggered cells.

Rows are non-exclusive: a project can appear in more than one category, so the sum of the Projects column can exceed 72 classified projects.

Keywords per category (what was counted):

• Dosimetry Methods and Quantification: dosimetry, absorbed dose, dosimetric, internal dosimetry, personalized dosimetry, organ dosimetry, tumor dosimetry, mird formalism, monte carlo dosimetry, dose calculation
• PET Imaging for Theranostics: pet imaging, pet/ct, positron emission tomography, pet theranostic, psma pet, 68ga pet, 18f pet, fdg pet, pet dosimetry, pet quantification
• SPECT Imaging and Scintigraphy: spect imaging, spect/ct, single photon emission, scintigraphy, spect dosimetry, planar scintigraphy, gamma camera, spect quantification
• Theranostic Paired Agents and Matched Ligands: theranostic, theranostics, theranostic pair, matched pair, diagnostic-therapeutic pair, see and treat, theranostic agent, theranostic platform, theranostic radioligand
• Chelator Chemistry and Radiometal Conjugation: chelator, chelation, dota, nota, dtpa, macropa, bifunctional chelator, radiometal chelation, chelate stability, transchelation, antibody chelator conjugate
• Radiobiology and Biological Dosimetry: radiobiology, radiobiological, linear energy transfer, let, relative biological effectiveness, rbe, dna double strand break, bystander effect, crossfire effect, radiobiological modeling
• Biomarker-Guided Patient Selection and Response Monitoring: biomarker, predictive biomarker, response biomarker, patient selection, biomarker guided, treatment response, molecular biomarker, imaging biomarker, circulating biomarker, therapy response biomarker
• Radiopharmaceutical Synthesis and Radiolabeling: radiolabeling, radiochemistry, radiopharmaceutical synthesis, automated synthesis, gmp radiolabeling, radiolabeled conjugate, isotope labeling, radiotracer synthesis, kit formulation
• Pharmacokinetics and Biodistribution: pharmacokinetics, biodistribution, clearance, uptake kinetics, tumor uptake, normal tissue uptake, blood clearance, radiation pharmacology, tissue distribution, excretion
• Toxicity Assessment and Normal Tissue Protection: toxicity, normal tissue toxicity, nephrotoxicity, bone marrow toxicity, hematotoxicity, salivary gland toxicity, organ at risk, kidney protection, radioprotection, therapeutic index
• Combination Radioligand and Immunotherapy Integration: radioimmunotherapy, immune checkpoint blockade, car t cell, immunoradiation, abscopal effect, tumor immunomodulation, in situ radioimmunotherapy, vaccination radionuclide
• Target Expression Modulation for Radioligand Uptake: receptor upregulation, psma expression modulation, somatostatin receptor upregulation, target density enhancement, antigen expression, radioligand target sensitization, receptor regulation therapy

The Dosimetry, Imaging, and Theranostic Infrastructure dimension is the most heavily matched of the five, with 72 of 121 projects (59.5%) classified, and two categories stand out in scale: toxicity assessment and normal tissue protection at 19 projects (15.7%, $21.2M) and combination radioligand and immunotherapy integration also at 19 projects (15.7%, $20.1M), reflecting strong emphasis on safety characterization and immuno-oncology convergence. Theranostic paired agents and matched ligands appear in 24 projects (19.8%, $18.2M) with a broader NIH count of 50, which is markedly higher than most peer categories in this dimension (most fall between 0 and 8); this 50-count may partly reflect broad keyword overlap with theranostics language across cancer imaging and should be interpreted directionally. Biomarker-guided patient selection and response monitoring is represented by only 5 projects (4.1%, $5.5M) with a broader NIH count of 1, and radiopharmaceutical synthesis and radiolabeling and pharmacokinetics and biodistribution each appear in 2-3 projects (1.7-2.5%) with broader NIH counts of 0 - counts too low to draw coverage conclusions but noting their minimal footprint in the analyzed sample.

Confidence: High - Evidence: 72 of 121 projects classified, two categories at 15.7% each, theranostic paired agents broader NIH count of 50 flagged as potentially keyword-inflated.

Strategic Implications

The analyzed sample does not surface strong quantitative gap signals meeting the threshold for ranked white space opportunities, meaning no category combination clears the share-ratio and minimum count floor required for high-confidence differentiation framing. For a researcher writing an R01 or R21 in this space, the most useful strategic read from the data is that theranostic infrastructure and toxicity assessment are the densely funded anchors - proposals that instead foreground underrepresented intersections such as specific isotope classes in non-prostate indications, or scaffold types beyond antibody conjugates, may encounter less competition within the NIH portfolio as reflected in this sample, though the sparse broader NIH counts for those categories prevent a confident gap claim. Mechanistic combination strategies pairing radioligand therapy with modalities beyond checkpoint inhibition (which already has 11 projects at 9.1% of the sample in the Combination Strategy dimension) represent areas where the sample count is low and the broader NIH activity is similarly limited, suggesting early-stage R21 exploratory framing may be appropriate for novel combination hypotheses. These implications are directional rather than prescriptive given the absence of ranked opportunities and the conservative title-only floor of broader NIH counts.

Confidence: Low - Evidence: No ranked white space opportunities identified from the sample; implications derived from relative category sparsity only, not from share-ratio signals meeting the analysis threshold.

Research Positioning

Competitive Positioning

Among the funded projects, three broad technical approaches are active simultaneously: (1) target-specific radioligand/radiopharmaceutical therapy directed at defined surface antigens (PSMA, NTSR1, CD46, IL-13Rα2, DLL3, CXCR4, CD38, CD33, MUC1, and others), (2) alpha-emitter development and dosimetry (Ac-225, At-211, Pb-212, Ra-223, Bi-213), and (3) combination strategies pairing radioligand therapy with immune checkpoint inhibitors, CAR-T cells, PARP inhibitors, or external beam radiotherapy.

Confidence: High - Evidence: at least 30+ projects in the FULL PROJECT LIST explicitly address one or more of these three pillars, spanning UCSF, Johns Hopkins, Wisconsin, Michigan, Fred Hutch, Iowa, Sloan Kettering, and others, totaling well over $60M of the $113.8M sample.

A new entrant seeking differentiation within this sample faces the densest competition in PSMA-prostate and neuroendocrine tumor contexts; projects 5R01CA235741-06 (MELT/PSMA), ZIABC011895 (PSMA combination RLT), 5R01CA255925-04 (PSMA theranostics), and 5R01CA262675-04 (PSMA salivary gland toxicity) all address PSMA from distinct angles, suggesting that incremental PSMA-targeted approaches face a crowded prior-art field within this sample.

Confidence: High - Evidence: 4 distinct PSMA-focused projects identified by project number above, plus additional PSMA-adjacent work, across at least 4 separate institutions.

By contrast, solid tumor targets beyond prostate and neuroendocrine tumors (colorectal via NTSR1 in 5R01CA259168-05, mesothelioma in 5R01CA288612-02, glioblastoma in 1R21CA294042-01A1, triple-negative breast cancer in R37CA278744 and R01CA303986) each appear in relatively small clusters of one to two projects per indication within the sample, suggesting less prior-art density for entrants focusing on those tumor types.

Confidence: Medium - Evidence: 5-7 non-prostate/non-NET solid tumor projects identified across the FULL PROJECT LIST; pattern holds across multiple institutions but each indication cluster is small (1-2 projects).

Multi-Method Concentration Patterns

Among the funded projects, the University of California San Francisco holds 8 projects spanning at least four distinct methodological categories: PSMA expression modulation (5R01CA235741-06), TGFβ-targeted theranostics (5R01CA297601-02), CD46 theranostics for myeloma (5R01CA271606-04 and R01CA279203), AML radioimmunotherapy (R01CA297845), and combination immunotherapy with radioligand therapy (5P50CA275741-02), representing one of the broader within-institution methodological distributions in this sample.

Confidence: High - Evidence: 8 projects listed under UCSF in the FUNDING BY ORG table, confirmed by 6 distinct project entries across multiple therapeutic targets and tumor types in the FULL PROJECT LIST.

Johns Hopkins holds 6 projects spanning dosimetry methodology (5R01CA240779-06, 5P01CA272222-03), alpha-particle radiobiology, in vivo multi-isotope autoradiography (R01CA297470), glutamine metabolism and RPT efficacy (R01CA295705), and low molecular weight theranostics (R01CA299906), representing a concentration of quantitative dosimetry and radiobiology work alongside target development within a single institution.

Confidence: High - Evidence: 6 projects confirmed in FUNDING BY ORG table; project numbers above map to distinct methodological categories in the FULL PROJECT LIST.

The University of Wisconsin-Madison holds 7 projects that span tumor immunomodulation via targeted radionuclide therapy (5P01CA250972-05), head and neck cancer immune priming (5P50CA278595-09), CAR-T enhancement in neuroblastoma (5K08CA285941-02), radiochemistry for copper-based radiopharmaceuticals (R01EB032349), NF-kB signaling in radiation therapy (5R01CA246321-05), and a radiotherapeutic paradigm for breast cancer (1R01CA295576-01A1), making it one of the more method-diverse multi-project concentrations in the sample.

Confidence: High - Evidence: 7 projects confirmed in FUNDING BY ORG table; project entries in FULL PROJECT LIST span immunology, radiochemistry, and clinical translation.

Methodological Trends

The most prominent methodological pattern among funded projects is the pairing of diagnostic imaging agents with therapeutic radioisotopes within a single molecular construct - the theranostic or theragnostic paradigm - appearing across a large share of the sample: projects targeting PSMA (5R01CA255925-04), TGFβ (5R01CA297601-02), CD46 (5R01CA271606-04), MUC1 (R37CA278744), Pb-203/212 pairs (R35CA232130, 5R37CA282650-03), melanocortin-1 receptor (5R01CA269221-03), and others all explicitly invoke matched imaging-therapy isotope pairs, indicating that theranostic design is now a baseline expectation rather than a novel differentiator within this funded sample.

Confidence: High - Evidence: 10+ projects across at least 7 institutions explicitly use 'theranostic' framing or matched diagnostic-therapeutic isotope pairs in titles or abstracts, corroborated by FULL PROJECT LIST entries.

Alpha-emitter development represents an emerging methodological priority relative to the longer-established beta-emitter (Lu-177, Y-90, I-131) work: projects 5R01CA243014-06 (Pb-212 alpha PRRT), 5P01CA272222-03 (alpha-particle dosimetry and radiobiology), R01CA240711 (Ra-223 combinations), 5R01CA262675-04 (PSMA alpha toxicity), R01CA303804 (At-211 CD45), 5R01CA269221-03 (Pb-212 melanoma), and 1P50CA302572-01 (CXCR4 alpha therapy) collectively reflect a growing emphasis on high-LET agents, though the infrastructure for alpha-emitter dosimetry and imaging is still being actively developed within the same sample rather than being a solved problem.

Confidence: High - Evidence: 7+ distinct alpha-emitter projects by project number confirmed above, spanning Iowa, Johns Hopkins, Washington University, Sloan Kettering, Wisconsin, Fred Hutch, and Iowa again, totaling multi-million-dollar allocations.

A third pattern is the integration of computational and dosimetry-based personalization tools alongside bench and translational work: projects 5R01CA289631-02 (biomarker/dosimetry-guided personalization), 5R01CA240706-05 (theranostic dosimetry planning for the nuclear medicine clinic), 5R01CA296305-02 (deep learning treatment planning for PSMA RPT), and R01CA297470 (in vivo 3D multi-isotope autoradiography) reflect a methodological push toward individualized absorbed-dose planning that sits adjacent to but distinct from the radiochemistry and biology work, suggesting the sample rewards projects that bridge quantitative dosimetry with therapeutic development rather than treating them as separate tracks.

Confidence: Medium - Evidence: 4 dosimetry/computational projects confirmed by project number above across Michigan, Johns Hopkins, and Yale; pattern is consistent but the cluster size (4 projects) limits confidence in its generalizability across the full NIH portfolio.

NIH Funding Landscape

Among the examined projects, our analysis reveals a dominant focus on targeted radionuclide therapy (TRT) and radiopharmaceutical therapy (RPT), with the majority of the 121 sampled projects classified under therapeutics (91 of 121). Scientific investment centers heavily on three converging axes: pairing alpha- and beta-emitting isotopes with tumor-selective targeting vectors (antibodies, peptides, small molecules), optimizing dosimetry and personalization for agents such as 177Lu-PSMA-617, and combining RPT with immune checkpoint inhibitors or CAR-T cells to generate systemic anti-tumor immunity. The sample shows particularly strong activity in PSMA-targeted prostate cancer, neuroendocrine tumors via PRRT with 203Pb/212Pb or 177Lu-DOTATATE, and emerging indications including glioblastoma, acute myeloid leukemia, triple-negative breast cancer, and colorectal cancer, suggesting that the field is expanding beyond its established thyroid and neuroendocrine base. Institutional concentration at UCSF ($9.0M), Johns Hopkins ($8.8M), and NCI intramural programs ($10.8M across Division of Basic Sciences projects) may reflect both longstanding radiopharmaceutical infrastructure and the availability of cyclotron or isotope production facilities, though two data points per institution do not establish a sustained funding trend.

Funding Summary

Funding figures sum award amounts across all budget periods for each project. Each fiscal year reflects actual spend in that year, not the most recent budget period only. Totals only include projects that meet the topic-relevance threshold - umbrella support grants (e.g., P30 cancer centers) that host a relevant trial but cover many unrelated programs are intentionally excluded so the headline number stays topically attributable.

Funding by Year

The Projects column counts each project in every year it received funding, so per-year counts sum to more than the 121-project sample total. Funding amounts are actual per-year spend from NIH RePORTER budget-period rows.

Through August 2026; FY2026 ends Sep 30, 2026. The YTD figure should not be compared directly to fully-reported prior years.

Top Funding Categories

Key Research Projects

Top Funded Projects

Funding is the sum of award totals across all budget periods for each project. Latest activity is the most recent fiscal year the project received an award. Category is auto-assigned by AI classification and may occasionally misassign monitoring-oriented diagnostic projects as therapeutics - the abstract is the ground truth for what the project actually does.

1. Imaging, Dosimetry and Radiobiology for α-particle Emitter Radiopharmaceutical Therapy

• PI: KIESS, ANA PONCE, Johns Hopkins University
• Funding: $5.7M (latest activity FY2025)
• Category: Therapeutics

Insight: This P01 program directly addresses a critical operational gap in alpha-particle radiopharmaceutical therapy: the absence of individualized dosimetry that forces clinicians into prolonged, suboptimal multi-cycle regimens calibrated for population-level toxicity rather than patient-specific organ tolerance. By developing dosimetry methodologies tailored to alpha-emitters - where short pathlength and high linear energy transfer make conventional beta-emitter dosimetry frameworks inadequate - this project bridges the methodological lag between clinical alpha-RLT deployment and the treatment-planning infrastructure needed to support it. At $5.7M, it is the largest single award in the analyzed sample and is positioned at exactly the intersection the broader report identifies as underdeveloped: dosimetry infrastructure for emerging alpha-emitter programs.

Alpha-particle emitter radiopharmaceutical therapy (αRPT) is being administered in a prolonged multi-cycle scheme that severely compromises the potential efficacy of this treatment modality. Dosimetry would make it possible to project potential normal organ toxicity for individual patients so that t...

View Project ->

2. Molecularly Targeted Radiosensitization of Locally Advanced Cancers

• PI: LAWRENCE, THEODORE S, University of Michigan at Ann Arbor
• Funding: $4.0M (latest activity FY2025)
• Category: Infrastructure

Insight: This SPORE infrastructure grant targets radiosensitization by combining external radiotherapy with agents that exploit the molecular drivers of breast, brain, and pancreatic cancers, emphasizing both tumor cell kill and immune activation as co-equal mechanisms. While the project does not center on radioligand therapy directly, its integrated preclinical-to-clinical design and focus on RT-immunotherapy synergy are methodologically adjacent to combination RLT strategies, particularly the RLT-plus-checkpoint-inhibitor cluster identified across the broader sample. Its relevance to the RLT field lies in generating transferable mechanistic data on how radiation-induced immunogenicity can be amplified through molecular targeting, a principle applicable to internally delivered radionuclides as well as external beam.

(Overall) The overarching hypothesis of this SPORE proposal is that combining RT with systemic therapy that targets the molecular drivers of locally advanced cancers will improve the outcome of treatment. We do not know of another group that can carry out integrated preclinical and clinical studies ...

View Project ->

3. Molecular Targeted Radionuclide Therapy for Tumor Immunomodulation and Enhancing Immunotherapy Response

• PI: WEICHERT, JAMEY P, University of Wisconsin-Madison
• Funding: $2.4M (latest activity FY2024)
• Category: Therapeutics

Insight: This project investigates how targeted radionuclide therapy reshapes the tumor immune microenvironment - specifically whether radiation-induced damage signals can enhance recognition by endogenous immune cells and potentiate diverse immunotherapy modalities including checkpoint inhibitors. The pan-cancer framing, rather than a single tumor type, is strategically notable because it tests whether immunomodulatory effects of RLT are a generalizable property or target- and tissue-dependent, a question with direct implications for designing combination clinical trials. This work sits at the mechanistic interface between RLT and immuno-oncology, an area that the broader sample identifies as a growing funded cluster but one where causal mechanistic data remain sparse.

OVERALL Targeted radionuclide therapies are a type of cancer treatment that can be injected into a patient’s vein and, after circulating through the patient’s body, these will preferentially accumulate in tumors and selectively deliver radiation to these locations. Radiation can damage tumors in a w...

View Project ->

4. PLK1 and EGFR targeted nanoconstruct as a monotherapy and a radiation sensitizer for lung cancer

• PI: NGAMCHERDTRAKUL, WORAPOL, Pdx Pharmaceuticals, Inc.
• Funding: $2.2M (latest activity FY2025)
• Category: Biotools

Insight: This project develops a nanoparticle construct co-targeting PLK1 and EGFR as both a standalone therapy and a radiation sensitizer for lung cancer, aiming to address the roughly 50% of patients with EGFR-relevant tumors regardless of specific mutation. Its connection to RLT is indirect - the radiation sensitization angle is relevant to any radiation modality, including internally delivered radionuclides - but the nanoconstruct delivery platform and dual-target molecular design represent a biotools-category approach that could inform ligand engineering strategies in radioligand programs. The project's distinctiveness lies in combining siRNA-based PLK1 knockdown with EGFR targeting in a single nanoconstruct, a multiplexed approach not commonly seen in the radiosensitization literature.

Lung cancer is the leading cause of cancer deaths, accounting for 25% of all cancer mortalities - more than colon, breast, and prostate cancer combined. We propose to develop a nanotherapeutic named PETTRA that simultaneously targets PLK1 and EGFR in approximately 50% of all lung cancer patients reg...

View Project ->

5. Combining Targeted RIT and Synergistic Novel Agent-Renewal

• PI: OROZCO, JOHNNIE JOSE, Fred Hutchinson Cancer Center
• Funding: $2.2M (latest activity FY2025)
• Category: Therapeutics

Insight: This project pursues radioimmunotherapy for acute myeloid leukemia by systematically identifying synergistic combinations with approved targeted agents and evaluating these combinations as conditioning regimens prior to allogeneic bone marrow transplantation, leveraging the established radiosensitivity of hematologic malignancies. The three-pronged design - combination identification, DNA damage correlation, and transplant conditioning application - positions the work to generate both mechanistic and clinically actionable outputs within a single grant. It is notably complementary to the CD33-directed At-211 program at the same institution, and together these two Fred Hutchinson projects represent a coordinated institutional bet on RLT as a backbone for AML treatment intensification.

(From Parent Grant Application) Although favorable responses have been attributed to recently approved targeted agents for the treatment of hematologic malignancies, such as acute myeloid leukemia (AML), the diversity of genetic mutations within blood cancers limits the curative potential of targete...

View Project ->

6. Radiation-induced molecular targets

• PI: COLEMAN, NORMAN (contact), Division of Basic Sciences - Nci
• Funding: $2.1M (latest activity FY2024)
• Category: Basic Research

Insight: This NCI intramural program on radiation-induced molecular targets supports basic mechanistic research into how radiation exposure alters cellular and molecular state, providing foundational knowledge relevant to both external beam and radioligand therapy contexts. Without a public abstract, the specific targets and experimental systems cannot be assessed, but its categorization as basic research within an NCI division suggests it functions as a discovery-oriented complement to the predominantly translational and clinical projects in this sample. Its value to the RLT field likely lies in identifying targetable vulnerabilities or resistance mechanisms induced by radiation, an area the broader report notes is sparsely covered among the analyzed projects.

View Project ->

7. Novel Approaches to CD33-Directed Radioimmunotherapy

• PI: WALTER, ROLAND BRUNO, Fred Hutchinson Cancer Center
• Funding: $2.0M (latest activity FY2026)
• Category: Therapeutics

Insight: This project develops At-211-based radioimmunotherapy directed at CD33, a clinically validated AML surface antigen, with the alpha-emitter chosen specifically for its short pathlength - suited to eliminating dispersed leukemic cells while limiting dose to surrounding marrow stroma. The explicit consideration of both transplant and non-transplant settings expands the potential patient population beyond the conditioning-regimen niche, and the absence of long-lived daughter isotopes from At-211 decay is highlighted as a safety-relevant property distinguishing it from other alpha emitters such as Ac-225. This project exemplifies the alpha-emitter chelator-and-biology development cluster identified in the broader sample, where isotope-specific physical properties are being deliberately matched to disease biology rather than applied generically.

CD33 is a validated drug target for acute myeloid leukemia (AML), but existing therapeutics are ineffective in many patients. Since AML cells are highly sensitive to radiation, we plan to develop and optimize a new form of CD33-directed radioimmunotherapy with astatine-211 for use in transplant and ...

View Project ->

8. Systematic evaluation of toxicity and therapeutic efficacy in CD46 directed radioligand therapy

• PI: FLAVELL, ROBERT RICHARD, University of California, San Francisco
• Funding: $2.0M (latest activity FY2026)
• Category: Therapeutics

Insight: This project develops CD46-directed radioimmunotherapy for prostate cancer, with CD46 selected as a target because of its overexpression in treatment-resistant and metastatic prostate cancer subtypes that often downregulate PSMA - the dominant clinical RLT target. The methodological emphasis on microscale dosimetry and metabolomic readouts alongside histology provides a more granular toxicity and efficacy characterization than is standard in preclinical RLT studies, and the use of clinically relevant metastatic models strengthens translational inference. Strategically, a CD46-targeting program addresses the PSMA-resistance and antigen-loss problem that a handful of projects in the broader sample are beginning to engage, and the novel chemical optimization of radionuclide delivery reflects active chelation and conjugation chemistry development.

This proposal describes the development and optimization of CD46 targeted radioimmunotherapy, and the systematic testing and evaluation of the method in preclinical models of prostate cancer. Novel chemical methodology is utilized to optimize the delivery of therapeutic radiation to tumor while mini...

View Project ->

9. Radiopharmaceutical Imaging and Therapy of Cancer

• PI: CHOYKE, PETER L (contact), Division of Basic Sciences - Nci
• Funding: $1.9M (latest activity FY2024)
• Category: Basic Research

Insight: This NCI intramural program on radiopharmaceutical imaging and therapy encompasses both diagnostic and therapeutic radiopharmaceutical development, positioning it as a theranostic-oriented program that bridges the imaging and treatment functions central to precision RLT. The absence of a public abstract limits detailed method-level analysis, but the dual imaging-therapy mandate and NCI Basic Sciences divisional home suggest it serves as a platform for early-stage radiopharmaceutical candidate evaluation that feeds into translational pipelines. Its presence alongside the radiation-induced molecular targets program at NCI reflects an institutional investment in maintaining intramural capacity across the basic-to-translational RLT spectrum.

View Project ->

10. Development of a theragnostic radiopharmaceutical for pancreatic cancer

• PI: FERRARA, KATHERINE W, Stanford University
• Funding: $1.9M (latest activity FY2026)
• Category: Therapeutics

Insight: This project identifies claudin-4 as a theranostic target in pancreatic cancer using spatial transcriptomics and multiplexed protein profiling of human tumor tissue, then develops peptide-based radioligands for both imaging and therapy - a target-discovery-to-radiopharmaceutical pipeline within a single grant. Pancreatic cancer is a high-unmet-need indication where existing RLT programs are sparse, making this one of the few sample projects explicitly addressing this tumor type with a radionuclide therapy approach. The use of spatially resolved multi-omic target identification to rationally select a peptide-targetable antigen represents a more data-driven target validation strategy than is typical in early RLT programs, and the claudin-4 selection specifically addresses the challenge of finding targets with sufficient tumor-restricted expression for safe systemic radionuclide delivery.

This proposal seeks to engineer a targeting ligand for molecularly-specific treatment via peptide targeted radionuclide therapy (PTRT) in pancreatic cancer. Spatial sequencing of human pancreatic tumors with both spatial transcriptomics and CODEX (protein) allowed us to identify claudin-4 as a promi...

View Project ->

Market Context

Market Overview

Market context below is synthesized from current web search results. See sources at the end of this section. NIH funding patterns are integrated to bridge public research and commercial activity.

Radioligand therapy (RLT) is an oncology modality that links a tumor-targeting ligand to a therapeutic radioisotope - most commonly lutetium-177 (Lu-177) - to deliver localized radiation directly to cancer cells while sparing healthy tissue. The commercial foundation of the market rests on two Novartis-owned Lu-177 products: Lutathera (approved 2018 for gastroenteropancreatic neuroendocrine tumors) and Pluvicto (approved 2022 for PSMA-positive metastatic castration-resistant prostate cancer). Together, these two therapies generated approximately $2.7 billion in 2025 revenues, with Pluvicto reaching roughly $1.9-2.0 billion and Lutathera approximately $816 million, representing the commercial core of the market. A key 2025-2026 inflection has been 'line migration' - the expansion of RLT use to earlier treatment settings. In March 2025, the FDA expanded Pluvicto's label to the pre-taxane setting in mCRPC, approximately tripling the eligible patient population, based on the Phase III PSMAfore trial. In July 2026, the FDA further approved Pluvicto in combination with androgen receptor pathway inhibitor (ARPI) therapy for metastatic hormone-sensitive prostate cancer (now termed mAPMN/S), supported by the PSMAddition trial, which showed radiographic progression-free survival benefit though overall survival data were still maturing at the time of initial reporting.

The next wave of RLT innovation is advancing on two fronts: expansion to new tumor targets (breast, lung, glioblastoma, lymphoma) and a shift toward alpha-emitting isotopes such as actinium-225 (Ac-225) and lead-212 (Pb-212), which offer shorter range and potentially higher per-cell lethality than beta-emitters. ITM Isotope Technologies' Lu-177 edotreotide (ITM-11) for GEP-NETs has a PDUFA date of August 28, 2026, which - if approved - would introduce competition to Lutathera in the neuroendocrine tumor setting. The field is also tracking several Phase 3 readouts expected in 2026 for next-generation RLT candidates. Isotope supply, particularly for Ac-225, represents a material operational bottleneck; at least one developer has reportedly paused a Phase 3 trial due to insufficient Ac-225 supply, and companies are raising dedicated capital to solve manufacturing and logistics constraints inherent to short-half-life radiopharmaceuticals.

Market Sizing: $2.6 billion in 2025, projected to $4.8 billion by 2030 at a 13.1% CAGR (ResearchAndMarkets / BCC Research, 'Radioligand Therapeutics in Cancer Treatment: Global Markets,' February 2026). Note: multiple market research firms have published materially different estimates for 2025 (ranging from approximately $2.6B to $6.6B), reflecting differences in scope definition and methodology; the BCC/ResearchAndMarkets figure is cited here as one of the most recently dated named reports with a clear scope boundary.

Key Players

These players are identified from market reports and trade press, and may differ from the NIH-funded organizations analyzed elsewhere in this report.

• Novartis (Pluvicto, Lutathera, 225Ac-PSMA-617 pipeline, Mariana Oncology acquisition)
• Bayer (Xofigo / radium-223 dichloride for bone-metastatic prostate cancer)
• Eli Lilly (Point Biopharma acquisition - PNT2002, PNT2003; Aktis Oncology collaboration; Radionetics Oncology option)
• AstraZeneca (Fusion Pharmaceuticals acquisition - FPI-2265, actinium-225 platform)
• Bristol Myers Squibb (RayzeBio acquisition - actinium-225 platform)
• ITM Isotope Technologies Munich (ITM-11 / Lu-177 edotreotide, PDUFA August 2026)
• Lantheus Holdings (radiopharmaceutical diagnostics and manufacturing integration)
• Telix Pharmaceuticals (TLX591-Tx therapeutic pipeline, Regeneron partnership April 2026)
• Curium Pharma (Lu-177 PSMA-I&T pipeline)
• ARTBIO (AB001, Pb-212 alpha RLT for mCRPC)
• Clarity Pharmaceuticals (67Cu-SAR-bisPSMA)
• Convergent Therapeutics (CONV 01-alpha, Ac-225 PSMA)
• Perspective Therapeutics
• Sanofi (lead-212 licensing partnership)

Recent Developments

• 2024-06: AstraZeneca announced acquisition of Fusion Pharmaceuticals for up to approximately $2.4 billion (completed June 2024), securing an actinium-225-based radioconjugate platform including FPI-2265 for prostate cancer
• 2024-01: Bristol Myers Squibb acquired RayzeBio for approximately $4.1 billion, gaining an actinium-225-based radiopharmaceutical platform
• 2024-01: Novartis acquired Mariana Oncology for $1 billion upfront plus up to $750 million in milestones, adding a preclinical RLT pipeline including a small cell lung cancer program
• 2024-01: Eli Lilly completed acquisition of Point Biopharma for approximately $1.4 billion, entering the RLT market with late-stage candidates PNT2002 (prostate cancer) and PNT2003 (NETs)
• 2025-03: FDA approved expanded label for Novartis Pluvicto in pre-taxane mCRPC (after ARPI therapy), based on Phase 3 PSMAfore trial results, approximately tripling the eligible patient population
• 2025-06: FDA approved label expansion for Ga-68 gozetotide (Illuccix) companion imaging agent to include patient selection for pre-taxane RLT, supporting Pluvicto's broader use
• 2025-09: FDA cleared ARTBIO's IND application for AB001, a Pb-212 alpha radioligand for mCRPC, enabling Phase 1 trial initiation
• 2026-08: ITM Isotope Technologies announced FDA acceptance of NDA for ITM-11 (Lu-177 edotreotide) for GEP-NETs with PDUFA goal date of August 28, 2026, supported by positive Phase 3 COMPETE trial data
• 2025-11: Novartis reported positive Phase 3 PSMAddition data showing radiographic progression-free survival benefit for Pluvicto in metastatic hormone-sensitive prostate cancer, though overall survival data were immature at reporting
• 2025-12: AdvanCell raised a $112 million Series C to advance targeted alpha manufacturing and clinical programs
• 2025-02: Eli Lilly entered strategic collaboration with AdvanCell to develop novel targeted alpha therapies
• 2026-01: Novartis signed worldwide exclusive license with Zonsen PepLib Biotech for an undisclosed peptide-based RLT asset, including a $50 million upfront payment
• 2026-01: Novartis announced plans to establish a fourth RLT manufacturing facility in Winter Park, Florida, signaling continued capacity expansion
• 2026-01: Telix Pharmaceuticals reported FY2025 revenues of approximately $804 million, driven largely by the US launch of Gozellix (Ga-68 PSMA imaging agent)
• 2026-04: Regeneron Pharmaceuticals entered a collaboration with Telix Pharmaceuticals to co-develop and co-commercialize next-generation radiopharmaceutical therapies
• 2026-07: FDA approved Pluvicto in combination with ARPI for adults with PSMA-positive metastatic androgen pathway modulation-naive or -sensitive (mAPMN/S) prostate cancer, the first RLT approval in the hormone-sensitive prostate cancer setting

Competitive Landscape

The RLT competitive landscape is bifurcated between Novartis as the incumbent commercial leader and a cohort of large-cap challengers - Eli Lilly, AstraZeneca/Fusion, Bristol Myers Squibb/RayzeBio, Bayer, and Sanofi - who entered via major acquisitions totaling more than $13 billion since 2023. The near-term competitive focus is on the PSMA-positive prostate cancer setting, where Novartis' Pluvicto dominates but faces potential pressure from AstraZeneca's actinium-225 agent FPI-2265 and Curium Pharma's Lu-177 PSMA-I&T as they advance through Phase 3. In the neuroendocrine tumor setting, ITM-11 (with a PDUFA date of August 28, 2026) would be the first direct competitor to Lutathera if approved. Competition is also emerging at the platform level: beta-emitter Lu-177 programs face differentiation pressure from alpha-emitting programs (Ac-225, Pb-212, At-211) that promise shorter-range, higher-LET cell killing - a shift that partly explains why BMS and AstraZeneca each paid large premiums specifically for actinium-225 access. A critical competitive constraint for all players is isotope supply, particularly Ac-225, where demand is reported to be outrunning capacity and at least one program has reportedly paused a Phase 3 trial for lack of supply - a logistics and manufacturing challenge that could reshape competitive standings independently of clinical outcomes. A parallel driver of competitive positioning is the 'line migration' dynamic: therapies demonstrating efficacy in earlier treatment lines dramatically expand eligible patient populations and revenue potential, as illustrated by Pluvicto's label expansions in 2025 and 2026. Specialist biotech entrants including ARTBIO, Clarity Pharmaceuticals, Convergent Therapeutics, Perspective Therapeutics, and Aktis Oncology are pursuing differentiated isotope and target combinations that could represent partnership or acquisition targets for large-cap players continuing to build out their radiopharmaceutical platforms.

Sources

Live web sources retrieved during report generation. Click to verify.

• www.precedenceresearch.com/radioligand-therapy-market
• www.globenewswire.com/news-release/2026/04/02/3267639/0/en/Radioligand-Therapy-Market-Expected-to-Surge-to-10-72-Billion-by-2030-Upsurge-in-Cancer-Cases-Fuelling-Industry-Growth-at-10-CAGR.html
• www.fortunebusinessinsights.com/radioligand-therapies-market-115467
• www.insightaceanalytic.com/report/global-radioligand-therapy-market/1281
• www.grandviewresearch.com/industry-analysis/radiation-oncology-market
• www.datamintelligence.com/research-report/radioligand-therapy-market
• www.marketsandmarkets.com/Market-Reports/radioligand-therapy-rlt-market-238791830.html
• www.openpr.com/news/4573234/radioligand-therapy-market-to-reach-us-15-80-billion-by-2033-as
• www.intelmarketresearch.com/radioligand-therapy-drugs-for-cancer-market-28187
• www.globenewswire.com/news-release/2026/02/19/3240998/28124/en/Radioligand-Therapy-Market-to-Surge-with-13-1-CAGR-Projected-Growth-from-2-6B-in-2025-to-4-8B-by-2030-Novartis-Pluvicto-and-Lutathera-Have-Catalyzed-Commercial-Momentum.html

Clinical Development Pipeline

Note: This analysis includes only clinical trials linked to NIH-funded projects. Industry-sponsored and international trials may exist outside this sample.

The linked trial sample spans 70 trials in progress, planned, or completed versus a smaller subset of terminated, withdrawn, or suspended studies, with 5 terminated and 2 withdrawn trials present - signaling that the field has experienced meaningful setbacks alongside its advances. Among active and recruiting studies, PSMA-targeted 177Lu therapy for metastatic castration-resistant prostate cancer is the most prominently represented indication, with multiple trials enrolling patients for dosimetry optimization and resistance mechanism studies rather than pivotal efficacy, reflecting a post-approval maturation phase following the FDA's 2022 Lu-PSMA-617 authorization. Early-phase studies of 212Pb-labeled agents for neuroendocrine tumors represent a wave of alpha-emitter programs entering first-in-human testing, consistent with the heavy preclinical investment in alpha particle TRT seen in the funded project sample. The predominance of Phase 1 and observational/dosimetry designs across the trial set, combined with a smaller number of completed Phase 2 studies concentrated in lymphoma radioimmunotherapy, suggests the pipeline is bifurcated between a maturing PSMA-prostate axis and earlier-stage programs across multiple new tumor types.

Trial Summary

By Phase

By Status

Active Trials

Escalating Cycle 1 Dose of Lu-177-PSMA-617 for the Treatment of Metastatic Castration Resistant Prostate Cancer

• NCT ID: NCT07682649
• Phase: Not specified
• Status: NOT YET RECRUITING
• Sponsor: Not specified
• Conditions: Not specified
• Enrollment: Not specified

A Safety Study of 212Pb-Pentixather Radioligand Therapy

• NCT ID: NCT05557708
• Phase: EARLY_PHASE1
• Status: NOT YET RECRUITING
• Sponsor: Yusuf Menda
• Conditions: Carcinoid Tumor Lung, Neuroendocrine Tumor of the Lung, Carcinoma, Small-Cell Lung
• Enrollment: 20 participants

SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization

• NCT ID: NCT06389097
• Phase: Not specified
• Status: RECRUITING
• Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
• Conditions: Prostate Cancer, Advanced Cancer
• Enrollment: 80 participants

SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy

• NCT ID: NCT07096999
• Phase: Not specified
• Status: RECRUITING
• Sponsor: University of Michigan Rogel Cancer Center
• Conditions: Metastatic Castration-Resistant Prostate Carcinoma
• Enrollment: 60 participants

Comprehensive Assessment of Cancer Theranostic Response

• NCT ID: NCT06815354
• Phase: Not specified
• Status: RECRUITING
• Sponsor: AIQ Solutions
• Conditions: Prostate Cancer
• Enrollment: 32 participants

A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors

• NCT ID: NCT06148636
• Phase: EARLY_PHASE1
• Status: ACTIVE, NOT RECRUITING
• Sponsor: David Bushnell
• Conditions: Neuroendocrine Tumors, Neuroendocrine Tumor of the Lung, Neuroendocrine Tumor Grade 1, Neuroendocrine Tumor Grade 2, Neuroendocrine Tumor of Pancreas
• Enrollment: 24 participants

Mechanisms of Resistance to PSMA Radioligand Therapy

• NCT ID: NCT05435495
• Phase: Not specified
• Status: RECRUITING
• Sponsor: University of California, San Francisco
• Conditions: Prostate Cancer
• Enrollment: 125 participants

Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma

• NCT ID: NCT00036855
• Phase: PHASE1
• Status: TERMINATED
• Sponsor: National Cancer Institute (NCI)
• Conditions: AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma, Post-transplant Lymphoproliferative Disorder, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma
• Enrollment: 36 participants

S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma

• NCT ID: NCT00070018
• Phase: PHASE2
• Status: COMPLETED
• Sponsor: SWOG Cancer Research Network
• Conditions: Lymphoma
• Enrollment: 46 participants

Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

• NCT ID: NCT00073918
• Phase: PHASE2
• Status: COMPLETED
• Sponsor: Fred Hutchinson Cancer Center
• Conditions: Anaplastic Large Cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma, Waldenström Macroglobulinemia
• Enrollment: 111 participants

Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma

• NCT ID: NCT00088881
• Phase: PHASE2
• Status: TERMINATED
• Sponsor: National Cancer Institute (NCI)
• Conditions: Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Splenic Marginal Zone Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Testicular Lymphoma, Waldenström Macroglobulinemia
• Enrollment: 62 participants

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer

• NCT ID: NCT00089245
• Phase: PHASE1
• Status: ACTIVE, NOT RECRUITING
• Sponsor: Y-mAbs Therapeutics
• Conditions: Brain and Central Nervous System Tumors, Neuroblastoma, Sarcoma
• Enrollment: 177 participants

S0433 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma

• NCT ID: NCT00107380
• Phase: PHASE2
• Status: COMPLETED
• Sponsor: SWOG Cancer Research Network
• Conditions: Lymphoma
• Enrollment: 86 participants

Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma

• NCT ID: NCT00110071
• Phase: PHASE1
• Status: COMPLETED
• Sponsor: Fred Hutchinson Cancer Center
• Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma, Waldenström Macroglobulinemia
• Enrollment: 38 participants

N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma

• NCT ID: NCT00253435
• Phase: PHASE2
• Status: COMPLETED
• Sponsor: Children's Hospital Los Angeles
• Conditions: Neuroblastoma
• Enrollment: 50 participants

Patent Activity

Note: This analysis includes only patents linked to NIH-funded projects. Commercial patents and international filings may exist outside this sample. USPTO filing timelines also lag commercial activity by roughly 18-24 months, so very recent private R&D may not yet appear in patent data.

IP Landscape (this sample): Insufficient sample to characterize (5 grant-linked patents - a landscape label like "concentrated" or "fragmented" requires at least 10 patents to be meaningful; the shape below is descriptive of this specific sample, not the broader IP landscape)

Patent Holders in Sample: UNIVERSITY OF WISCONSIN-MADISON, UNIVERSITY OF IOWA

Recent Activity: None of the 5 linked patents were filed in the last 2 years, suggesting no recent NIH-linked patenting activity in this sample - though this may reflect the lag between NIH project reporting and patent linkage rather than an actual slowdown in the field.

Confidence: Low - Evidence: 0 of 5 linked patents filed within the last 2 years; sample size of 5 is insufficient to characterize broader filing trends.

Freedom to Operate Assessment

Among the NIH-linked patents in this sample, FTO concerns for a new entrant may include radioactive phospholipid metal chelate compositions (covering cancer imaging and therapy), targeted radiotherapy chelate constructs designed to modulate in situ immune responses, and peptide receptor-targeted radionuclide therapy optimization methods - all held by academic institutions where licensing terms are often negotiable but IP protections are real.

Confidence: Low - Evidence: 5 linked patents from 2 assignees; with a sample this small, the true commercial IP landscape - including patents from Novartis, Bayer, ITM, and other major radioligand therapy developers - is likely substantially larger and is not captured here.

A new entrant should run a full USPTO/Google Patents/PATENTSCOPE search against the specific technical methods present in this sample (chelate chemistry, phospholipid radiolabeling, peptide receptor targeting, theranostic optimization) before drawing FTO conclusions.

The 5 linked patents span 2 academic assignees - University of Wisconsin-Madison (3 patents) and University of Iowa (2 patents) - across the following technical areas: radioactive phospholipid metal chelation for theranostic use, in situ immune modulation via targeted radiotherapy chelates, and structural optimization of peptide receptor-targeted radionuclide therapy. This pattern, if it holds in a fuller search, may suggest that foundational NIH-supported work on radioligand chemistry and receptor targeting has been developed primarily in academic settings, with corresponding IP accessible through standard technology transfer channels.

Confidence: Low - Evidence: 5 linked patents from 2 assignees; commercial patent activity from pharmaceutical and radiopharmaceutical companies operating in this space is not represented in this NIH-linked sample and would require independent patent database searches to assess.

Strategic Implications

For a researcher working in or adjacent to radioligand therapy, these 5 linked patents identify two academic groups actively protecting chelate chemistry, immune-modulatory radiotherapy constructs, and peptide receptor targeting methods - areas that may overlap with preclinical or translational research programs. Before designing novel compounds or optimization strategies in these technical areas, the practical first step is a claim-level prior-art review against the specific methods present in this sample (phospholipid metal chelation, in situ immune vaccination via radiotherapy, and theranostic peptide receptor targeting) using a full USPTO/Google Patents/PATENTSCOPE search to identify both the full academic IP picture and any commercial filings not captured here. Academic IP from institutions like these is often available for licensing or collaborative research agreements, but knowing the exact claim scope - rather than just the patent titles - is what determines whether a proposed research direction requires licensing or can proceed independently.

Confidence: Low - Evidence: 5 linked NIH-associated patents from 2 assignees; the commercial radioligand therapy IP landscape from industry players is not reflected in this sample and the true IP environment is likely much larger.

Patent Analysis

Among the 5 linked patents, the IP activity spans 2 assignees - the University of Wisconsin-Madison (3 patents) and the University of Iowa (2 patents) - covering two distinct technical areas: radioactive phospholipid metal chelate compounds designed to combine tumor-selective retention with in situ immune modulation, and structural optimization of SSTR2-targeting peptide-chelator conjugates for theranostic PRRT. The Wisconsin patents cover both the imaging and therapeutic application of alkylphosphocholine-chelate analogs capable of carrying alpha, beta, or Auger emitters, as well as their combination with in situ tumor vaccination strategies, indicating a translational intent to merge radiotherapy and immunotherapy in a single molecular platform. The Iowa patents address carcinoma-targeting conjugates using SSTR2 ligands with tunable linker-chelator architectures, directly supporting the preclinical neuroendocrine tumor programs visible in the funded project list. The absence of recent patents filed within the prior two years, combined with the small number of linked IP documents, suggests that a meaningful portion of the translational innovation in this sample may reside in pending applications, materials transfer agreements, or unpublished filings not yet captured in this analysis.

Patent Summary

Key Patents

TARGETED RADIOTHERAPY CHELATES FOR IN SITU IMMUNE MODULATED CANCER VACCINATION

• Patent #: 10751430
• Assignee: UNIVERSITY OF WISCONSIN-MADISON

The disclosed method of treating a malignant solid tumor in a subject includes the steps of administering to the subject an immunomodulatory dose of a radioactive phospholipid metal chelate compound t...

RADIOACTIVE PHOSPHOLIPID METAL CHELATES FOR CANCER IMAGING AND THERAPY

• Patent #: 11186598
• Assignee: UNIVERSITY OF WISCONSIN-MADISON

Alkylphosphocholine analogs incorporating a chelating moiety that chelates a radioactive metal isotope are disclosed herein. The alkylphophocholine analogs, which can be used to treat or detect solid ...

Targeted Radiotherapy Chelates for In Situ Immune Modulated Cancer Vaccination

• Patent #: 11730834
• Assignee: UNIVERSITY OF WISCONSIN-MADISON

The disclosed method of treating a malignant solid tumor in a subject includes the steps of administering to the subject an immunomodulatory dose of a radioactive phospholipid metal chelate compound t...

Structural Optimization Method to Improve the Theranostic Performance of Peptide Receptor-Targeted Radionuclide Therapy for Cancers

• Patent #: 12337042
• Assignee: UNIVERSITY OF IOWA

The present invention provides in certain embodiments a carcinoma-targeting conjugate comprising Formula I:

T-L-X

wherein T is a SSTR2 targeting ligand, L is a linker, and X is a chelat...

STRUCTURAL OPTIMIZATION METHOD TO IMPROVE THE THERANOSTIC PERFORMANCE OF PEPTIDE RECEPTOR-TARGETED RADIONUCLIDE THERAPY FOR CANCERS

• Patent #: 12502442
• Assignee: UNIVERSITY OF IOWA

The present invention provides in certain embodiments a carcinoma-targeting conjugate comprising Formula I wherein T is a SST2R targeting ligand, L is a linker, and X is a chelator, for the therapeuti...

Key Publications

Note: This analysis includes only publications linked to NIH-funded projects and may not represent the complete body of literature in this field. PubMed indexing typically lags publication date by 1-3 months for peer-reviewed articles; preprints appear faster but are not peer-reviewed.

The 744 linked publications, led by the Journal of Nuclear Medicine (46 articles) and the International Journal of Radiation Oncology, Biology, Physics (27 articles), reflect a field that bridges nuclear medicine, radiation biology, and clinical oncology - with a publication base mature enough to sustain dedicated journal coverage but still generating substantial preprint activity (29 bioRxiv entries). Among the accessible publication abstracts, recurring scientific questions address the dosimetry of alpha-emitting radiopharmaceuticals and its translation into personalized treatment planning, the immunomodulatory consequences of targeted radionuclide therapy and how radiation-induced tumor antigen release can be harnessed in combination with checkpoint inhibitors, and the structural chemistry of lead-203/lead-212 theranostic pairs for image-guided alpha therapy in neuroendocrine tumors. Methodological advances evident in the sample include agent-based computational tumor models integrating Monte Carlo radiation transport for preclinical simulation (AMBER framework), deep semi-supervised transfer learning for whole-body tumor quantification on PET/CT, and activity-based chemical probes for mechanistic pathway dissection - tools that may support more rigorous preclinical-to-clinical translation in RPT programs. The co-occurrence of basic radiobiology publications alongside clinical real-world experience reports for 177Lu-PSMA-617 indicates a field operating simultaneously at multiple stages of scientific maturity.

Must-Read Publications

1. CD46-Targeted Theranostics for PET and 225Ac-Radiopharmaceutical Therapy of Multiple Myeloma.

• PMID: 38109209

Why it matters: Among the linked publications, this study develops and validates a CD46-targeted theranostic system pairing an immunoPET probe with 225Ac-based radiopharmaceutical therapy for multiple myeloma, demonstrating both imaging specificity and therapeutic efficacy in murine models. It exemplifies the paired diagnostic-therapeutic approach central to modern radioligand therapy and extends the strategy to a hematologic malignancy beyond prostate cancer.

Key finding: CD46-targeted 89Zr immunoPET imaging and 225Ac radiopharmaceutical therapy produced measurable tumor control and survival benefit in multiple myeloma xenograft models.

Publication Summary

• Total linked publications: 744
• Unique journals: 263

Top Journals:

• Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine (46)
• bioRxiv : the Preprint Server for Biology (29)
• International Journal of Radiation Oncology, Biology, Physics (27)
• Clinical Cancer Research : an Official Journal of the American Association for Cancer Research (25)
• Radiation Research (21)

Key Organizations

Top 15 of 52 funded organizations, ranked by NIH funding within the analyzed sample.

Trials, patents, and publications counted here are those where an NIH grant belonging to this org was acknowledged. Patent assignee, trial sponsor, and publication first-author affiliation may differ from the org named on the underlying NIH grant. See the Patent Activity section for a separate view by assignee.

Key Researchers

Next Steps

Concrete actions the report suggests based on what's above. Not exhaustive - use these as a starting checklist you can extend.

• [ ] Map the active methodological clusters before drafting your next proposal. Review the Key Research Projects table to identify which radioligand approaches (targeted alpha therapy, PSMA-directed agents, peptide-receptor radionuclide therapy, etc.) already have dense project coverage under the $113.8M NIH portfolio. Use this to position your proposal in a space that is either underserved or where your approach offers a distinct mechanistic angle not already represented across the 121 sampled projects.

• [ ] Verify any apparent funding gap before committing proposal effort. The Coverage Gap Signals section returned no white-space signals in this dataset. Before treating any sub-topic as an open lane, run a supplemental NIH RePORTER search using alternative MeSH terms and project keywords to check whether adjacent portfolios (radiochemistry, immunoconjugates, targeted drug delivery, nuclear medicine) already cover the work under different terminology. Draft a proposal targeting a gap only if the gap holds up after that cross-portfolio check.

• [ ] Benchmark your proposal narrative against funded abstracts in your methodological category. See the Key Research Projects table and filter by your primary approach (e.g., radiolabeled antibody, small-molecule ligand, dosimetry optimization). Read the funded abstracts in that cluster directly - not the PI list - to understand how reviewers have framed significance, innovation, and approach for successfully funded projects in this specific area.

• [ ] Select grant mechanisms matched to your project stage using the funding distribution in this report. The 121 projects span R01, R21, U01, and other mechanisms across 52 organizations. Review the Key Organizations table to see which mechanisms are most common for your project type and career stage. If you are proposing early feasibility work on a new radiolabeled construct, an R21 may align better with the scope seen in this portfolio; if you are proposing a multi-site dosimetry or biomarker study, review U01 activity in the sample before deciding.

• [ ] Run a full patent landscape search independent of this report's linked-patent count. Only 5 patents in the sample were linked to NIH grants, which is too small a number to characterize the IP distribution or identify freedom-to-operate signals. Search USPTO, Google Patents, and PATENTSCOPE using assignee, IPC class (e.g., A61K51), and compound-specific terms to build an accurate picture of filed IP in radioligand therapy before making any decisions about novel composition claims or licensing strategy.

• [ ] Cross-reference clinical trial activity against your proposed endpoints and patient populations. The 70 trials in the filtered sample reflect only trials acknowledging NIH funding; commercially sponsored and international trials are not captured in this sample in this count. Search ClinicalTrials.gov directly using your target analyte, cancer type, and radioligand modality to assess what endpoint packages, dosing regimens, and comparator arms are already in use, and to ensure your proposed trial design adds interpretable signal rather than duplicating existing work.

• [ ] Review the Key Organizations table to map institutional activity in your specific sub-area before planning any collaborative grant. If you are considering a multi-PI or consortium application, search the table for institutions active in the same methodological category as your project (e.g., alpha-emitter chemistry, imaging-therapy integration, tumor dosimetry). Use that as a starting point for your own RePORTER and PubMed searches to understand the collaboration landscape - rather than relying on the 52-organization sample alone, which reflects NIH-acknowledged funding only.

• [ ] Assess the trial-to-project ratio in your cancer-type focus area to calibrate translational feasibility framing. With 70 trials across 121 projects in the filtered sample, the overall ratio suggests moderate but uneven clinical translation activity. Use the Key Research Projects table to locate projects in your cancer-type cluster and check whether trials in that cluster are Phase I safety studies or later-stage efficacy trials. This will help you calibrate whether a new proposal should emphasize IND-enabling studies, biomarker development, or comparative efficacy - and how reviewers in your study section are likely to weight translational readiness.

About This Report

Methodology

This report analyzes a curated subset of NIH-funded research projects most relevant to Radioligand therapy for cancer. Projects were identified using semantic search (AI-based conceptual matching) and filtered by match quality.

Search Interpretation Used: Standard - "radioligand therapy and targeted radionuclide therapy for cancer treatment"

Note on Funding Figures: Per-project funding amounts shown in this report are the sum of award totals across all budget periods for each project (not just the most recent year). Funding-by-year figures show actual spend per fiscal year drawn from the underlying NIH RePORTER budget-period rows, so a multi-year project contributes to each year it received funding. The current NIH fiscal year (Oct 1 - Sep 30) is partial when this report is generated; that year is labeled "(YTD)" in tables and charts and should not be compared directly to fully-reported prior years.

Note on Funding Attribution: Clinical trials are surfaced through two paths - direct linkage to topically-relevant projects, and semantic similarity between the trial's own title and the topic (using the same vector-embedding mechanism that powers project search, gated by a dedicated trial-inclusion threshold). The second path catches trials that sit under broad institutional umbrella awards (e.g., P30 cancer center support grants, CTSA hubs) whose underlying parent grant covers many unrelated programs. Those trials are reported because their titles are clearly about the topic, but their umbrella grants' funding is not rolled into Total Committed Funding - only projects whose own abstracts clear the project-relevance threshold contribute to funding totals. This keeps the headline funding number topically attributable rather than inflated by institutional overhead grants that happen to host one relevant program among many.

Match Quality Tiers:

Sample Composition:

Sample Interpretation:

• All 121 matches are Precise (similarity ≥50%). This is not a tuned threshold - it reflects the topic mapping to a tightly-bounded research area where most relevant NIH grants land above the 50% similarity cutoff. Broader topics with less coherent literature produce mixed Precise + Balanced splits (typically 60/40 to 80/20). Note that "Precise" measures semantic similarity to the query, not perfect topical fit - a project can score above the threshold and still touch adjacent research areas (e.g., a project whose main focus is diagnostic biomarkers but whose abstract mentions sepsis biomarkers as comparator work). Treat this signal as "the field's vocabulary aligns well with our query," not as "every project is a pure topic match."

Linked Data:

Limitations

This analysis focuses on depth over breadth, capturing publicly-funded academic research. It does not include privately-funded industry R&D or international research outside NIH grants.

Data current as of August 7, 2026.